Any news on advancements in Parkinson's disease treatments or medication Long press to copy event ID, title, and status

On 23 October 2026, researchers at the Mayo Clinic announced a first-of-its-kind clinical trial investigating low-dose radiation as an anti-inflammatory treatment to slow the progression of early-stage Parkinson's disease. Additionally, new Phase 1 data for the experimental stem cell therapy XS411 showed significant improvements in motor function and quality of life, with the Phase 2 trial now fully enrolled. These developments coincide with the commercial launch of JUVMO (tavapadon) in the United States this month.

• Mayo Clinic low-dose radiation trial: On 23 October 2026, it was reported that the Mayo Clinic is conducting the first clinical trial to test low-dose radiation as an anti-inflammatory approach to slow symptom progression in early-stage Parkinson's patients.
• XS411 stem cell therapy Phase 1 results: New Phase 1 clinical trial data for Xellsmart's XS411, reported on 23 October 2026, showed the therapy was well tolerated and improved motor function; the company also confirmed the completion of patient enrollment for its Phase 2 trial.
• Long-term exercise study results: A study published in Neurology and highlighted on 23 October 2026 found that Parkinson's patients who exercised more than eight hours per week experienced significantly slower declines in memory and movement over a seven-year period.

On 20 October 2026, new clinical data for the Parkinson's treatment bezisterim was presented at the American Neurological Association (ANA) meeting, showing significant improvements in motor and non-motor symptoms for patients with high inflammation. This follows the recent FDA approval of JUVMO (tavapadon), a once-daily oral treatment that is expected to become available to U.S. patients throughout October 2026.

• BioVie bezisterim Phase 2 SUNRISE-PD results: On 20 October 2026, BioVie Inc. presented results from its Phase 2 trial of bezisterim (NE3107) at the ANA Annual Meeting, reporting that patients with high systemic inflammation showed statistically significant improvements in both motor and non-motor symptoms over 12 weeks.
• JUVMO (tavapadon) market availability: Following its FDA approval on 25 September 2026, JUVMO (tavapadon), the first selective D1/D5 receptor agonist for Parkinson's, is scheduled for commercial launch and availability in the United States during October 2026.
• Solengepras Phase 3 ARISE trial results: Detailed results from the Phase 3 ARISE trial presented in October 2026 confirmed that solengepras, a non-dopaminergic GPR6 inhibitor, significantly reduced daily 'off' time by approximately 37 minutes compared to placebo in patients with advanced Parkinson's.

Between 18 and 20 October 2026, several clinical and research milestones for Parkinson's disease were announced, including the first patient dosing in a Phase 1b trial for the mitochondrial-targeting treatment MTX325. At the 2026 International Congress of Parkinson's Disease and Movement Disorders, XellSmart presented successful Phase I results for its off-the-shelf cell therapy, XS411, and confirmed full enrollment for its Phase II trial. Additionally, new research presented at the American Neurological Association meeting established a significant link between low daily physical activity and increased risk of developing the disease.

• XellSmart XS411 Phase I results and Phase II enrollment: On 18 October 2026, XellSmart presented Phase I data for XS411, an off-the-shelf iPSC-derived cell therapy, showing sustained motor function improvements; the company also announced full enrollment for its Phase II trial in China.
• First patient dosed in MTX325 Phase 1b trial: Mission Therapeutics announced on 19 October 2026 that the first patient has been dosed in a Phase 1b trial of MTX325, an oral drug designed to improve mitochondrial health by blocking the USP30 enzyme.
• ANA 2026: Step count and Parkinson's risk study: A study presented on 19 October 2026 at the American Neurological Association meeting found that individuals averaging fewer than 5,000 steps daily had an 80% higher rate of Parkinson's and dementia compared to those walking over 12,000 steps.
• ANA 2026: VPS39 gene and lysosomal dysfunction: On 18 October 2026, researchers at the ANA meeting detailed how variants in the VPS39 gene cause neurological disorders through impaired lysosomal function, offering a new target for neurodegeneration therapies.

Between 15 and 17 October 2026, several key advancements in Parkinson's disease were reported, including the presentation of trial results for SNT-4728, which successfully reduced neuroinflammation in prodromal cases. Researchers also published a landmark study on 16 October detailing how failures in cellular recycling pathways drive the disease, while BioVie presented new clinical findings for bezisterim at the 2026 American Neurological Association meeting. Additionally, the first-in-class D1/D5 receptor agonist Juvmo (tavapadon) is expected to reach U.S. patients by the end of October 2026.

• SNT-4728 Trial Results for Prodromal Parkinson's: On 16 October 2026, results were highlighted for a trial of SNT-4728, a small molecule that significantly reduced neuroinflammation and improved physical rating scales in patients with isolated REM sleep behavior disorder, a precursor to Parkinson's.
• BioVie Bezisterim Presentation at ANA 2026: BioVie presented findings on bezisterim (NE3107) at the American Neurological Association Annual Meeting starting 17 October 2026, demonstrating improvements in inflammation markers and motor symptoms in early-stage patients.
• Landmark Cellular Recycling Study: A study published on 16 October 2026 revealed how the ubiquitin-proteasome pathway and SUMOylation processes fail in Parkinson's disease, providing a new target for drug discovery to improve protein clearance in neurons.
• Juvmo (Tavapadon) U.S. Patient Availability: Following its late September approval, reports on 16 October 2026 confirmed that AbbVie expects Juvmo, the first selective D1/D5 dopamine receptor agonist, to be available to U.S. patients by the end of October 2026.